Angiosarcoma is rare, and often portends adverse outcomes. Those who receives multi-modal care generally experience the best cancer outcomes. However, guidelines to inform approach are limited. Further education is needed to advocate for high-quality care in this uncommon setting.
This ASTRO-AstraZeneca SCLC Therapy Challenge Kick-Off, featuring Dr. Percy Lee, MD, FASTRO, introduces an innovative initiative focused on advancing treatment options for small cell lung cancer (SCLC).